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Abstract  
 
Background: Early age at first birth and multiparity reduce the risk of estrogen 
receptor and progesterone receptor (ERPR) positive breast cancer, whereas 
breastfeeding reduces the risk of both ERPR-positive and ERPR-negative cancers.  
 
Methods: We used multivariable logistic regression analysis to investigate whether 
age at first birth (</≥25 years) and breastfeeding (ever/never) modify the long-term 
effect of parity on risk of ERPR-positive and ERPR-negative cancer using 1457 
incident breast cancer cases and 1455 controls aged ≥ 55 years who participated in the 
Women’s Contraceptive and Reproductive Experiences Study. 
 
Results: Women who gave birth before age 25 years had a 36% reduced risk of breast 
cancer compared to nulligravida that was not observed for women who started their 
families at an older age (P heterogeneity=0.0007). This protective effect was 
restricted to ERPR-positive breast cancer (P heterogeneity=0.004). Late age at first 
birth increased the risk of ERPR-negative cancers.  
 
Additional births reduced the risk of ERPR-positive cancers among women with an 
early first birth (P trend=0.0001) and among women who breastfed (P trend=0.004), 
but not among older mothers or those who never breastfed. In women with a late first 
birth who never breastfed, multiparity was associated with increased risk of breast 
cancer.  
 
Conclusions: These findings suggest that the effect of parity on a woman’s long-term 
risk of breast cancer is modified by age at first full-term pregnancy and possibly by 
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breastfeeding.  
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Introduction  
Epidemiological studies have provided consistent evidence that reproductive factors 
are associated with breast cancer risk. Some of these associations vary depending on 
the hormone-receptor status of the tumor. A recent systematic review (1) and meta-
analysis (2) reported that parity and young age at first birth decrease the risk of 
estrogen receptor-progesterone receptor (ERPR) positive tumors, but do not impact 
the risk of ERPR-negative tumors. The meta-analysis also found that breastfeeding 
protects against both receptor positive and negative tumors (2). We have previously 
reported similar findings from the Women’s Contraceptive and Reproductive 
Experiences (CARE) Study (3). 
 
One area of uncertainty is whether age at first birth or breastfeeding modifies the 
effect of parity on the long term risk of ERPR-positive and ERPR-negative breast 
cancer. In the United States, mean age at first birth has continued to rise from 21.4 
years in 1970 to 24.9 years in 2000 (4). It is not clear whether the protective effect of 
parity on ERPR-positive tumors is as strong in women who start their families later, at 
age 25 years or thereafter. Further, it is unknown what the combined effect of 
breastfeeding and parity is in this group of women with later first birth.   
 
Since the immediate impact of a full-term pregnancy is a transient increase in breast 
cancer risk that may last as many as 10 to 15 years following the pregnancy (5,6) and 
older women have a higher proportion of ERPR-positive tumors than younger women 
(7), the long term effect of parity on the ERPR status of breast cancer may be 
optimally examined in women diagnosed with breast cancer at least 15 years after 
child-bearing age. Thus, in the present study, we investigated associations between 
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parity, age at first full-term pregnancy and breastfeeding on the risk of ERPR-positive 
and ERPR-negative breast cancer among women 55-64 years of age enrolled in the 
Women’s CARE Study.   
 
Methods 
The Women’s CARE Study is a population-based case-control study designed to 
examine risk factors for breast cancer among White and African-American women 
aged 35 to 64 years in five United States (US) regions (Atlanta, Seattle, Detroit, 
Philadelphia, and Los Angeles).  Study methods have been described in detail 
previously (8).  
 
Case patients 
Case patients were US-born, English-speaking women first diagnosed with a primary 
invasive breast cancer between July 1994 and April 1998. Case patients were 
identified by the Surveillance, Epidemiology, and End Results (SEER) cancer 
registries in Atlanta, Seattle, Detroit and Los Angeles, or from hospitals in 
Philadelphia. African-American women and younger White women were 
oversampled to provide approximately equal numbers of women in each five-year age 
category from 35 to 64 years and to maximize the number of African-American 
participants.  Of the 5,982 eligible case patients, 4,575 (76.5%), were interviewed 
(2,953 Whites and 1,622 African-Americans). 
 
Control subjects 
Control subjects were US-born, English-speaking women identified through random 
digit dialing (RDD); those eligible had no prior diagnosis of invasive or in situ breast 
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cancer.  Control subjects were randomly selected from the pool of RDD screened 
women and were frequency matched to case patients by study region, race, and five-
year age group.  Approximately 82% of residential households called were 
successfully screened.  Of the 5,956 eligible women selected as control subjects, 
4,682 (78.6%) were interviewed (3,021 Whites and 1,611 African-Americans). 
 
Data collection 
All participants were interviewed in person by trained interviewers who used a 
structured questionnaire.  Interview questions covered demographics, reproductive 
and breastfeeding history, medical history including body mass index (BMI) and use 
of postmenopausal hormones (PMH), family history of cancer and lifestyle factors.  
We established a reference date for each participant, the date of breast cancer 
diagnosis for case patients and the date on which the RDD screening questionnaire 
was administered by telephone for control subjects.  Interview information was 
collected up to each woman’s reference date. 
 
ER and PR status of case patients was recorded by each study center.  Overall, 3837 
(83.9%) cases had ER and PR status data available (range: Detroit 72.2%, Seattle 
93.6%).  
 
Data analyses 
 We conducted all analyses in three different patient groups: i) all cases combined; ii) 
ERPR-positive cases; and iii) ERPR-negative cases.  We restricted these analyses to 
women aged 55 years or older and excluded 7 women (3 cases and 4 controls) who 
did not provide complete information on pregnancy or breastfeeding history and one 
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case patient who had never menstruated. We considered any pregnancy lasting more 
than 26 weeks as a full-term pregnancy and excluded 84 women (41 cases and 43 
controls) who had only experienced short-term pregnancies because they do not share 
the same risk profile as nulligravid or parous women (9), leaving 1457 case patients 
and 1455 control subjects for our analyses of all cases combined. This combined 
analysis was conducted to maximize our power to estimate the overall effect of parity 
and breastfeeding on all tumor types.  Case patients without ER or PR status available 
(258 cases) or a borderline ER or PR status result (24 cases) were excluded from our 
analysis of associations by ERPR-status. We also excluded case patients with 
ER+PR- (165 cases), or ER-PR+ tumors (41 cases) from these analyses because these 
tumors may represent an intermediate risk group and there were too few to examine 
them separately (10); resulting in a total of 969 case patients for analyses according to 
ERPR status (708 ERPR-positive cases and 261 ERPR-negative cases).  
 
We recorded a woman’s age at first full-term pregnancy as the date of completion of 
this pregnancy.  We also refer to this as ‘age at first birth’. Women who ever breastfed 
for at least one day were classified as having a positive history of breastfeeding.  
 
We compared the distributions of reproductive and demographic characteristics by 
subject status (ERPR-positive case patients, ERPR-negative case patients and control 
subjects) using chi square tests. Multivariable polytomous logistic regression was 
used to calculate odds ratios (ORs) and 95% confidence intervals (CIs) for breast 
cancer by ERPR-status. In these analyses, we included categorical variables for age 
(55-59, 60-64 years), race (African American/White), and study center (5 sites).  We 
also adjusted for first degree family history of breast cancer (breast cancer in a mother 
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or sister: no, yes, unknown or adopted), age at menarche (<11, 12, 13, >14 years), and 
education (up to high school, technical school/some college, college graduate). Other 
potential confounders including BMI (weight (kg)/height (m)2), duration of hormone 
therapy (estrogen or estrogen plus progestin, never, <6 months use, ≥6 months use) 
and recent use of hormone therapy (never, within 6 months of reference date, ≥6 
months ago) altered point estimates by less than 5% and were not included in the 
model. In analyses limited to parous women, we also adjusted for age at first full-term 
pregnancy (≤19, 20-24, 25-29, ≥30 years), ever/never breast feeding and number of 
full-term pregnancies (1, 2, 3, 4+) where appropriate.  
 
We assessed the relationship between a full-term pregnancy and risk of breast cancer 
overall, and then assessed associations between parity, age at first full-term 
pregnancy, breastfeeding and breast cancer risk, stratified by age at first full-term 
pregnancy (< 25 years, ≥25 years) and breastfeeding history (ever, never) for all 
women included in this analysis and then among women with ERPR-positive breast 
cancer and ERPR-negative breast cancers. We evaluated a model that assessed the 
three-way interaction of number of births by breast feeding status by age at first birth 
on breast cancer risk. We do not present the results of this three-way interaction by 
ERPR tumor status due to the small numbers of ERPR-negative tumors available. The 
age at first full-term pregnancy cut-points used for stratification were based on 
previous epidemiological studies which showed reduced risk among women whose 
first pregnancy occurred before age 25 years (11,12).  
 
We tested for effect modification by age at first full-term pregnancy (</≥25 years) and 
breastfeeding history (ever/never) by testing for heterogeneity of the parity estimates 
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across categories of these effect modifiers as follows: We used a likelihood ratio test 
to compare the fit of a model with a binary variable or a trend variable for parity 
versus the fit of a model where the parity variable was allowed to vary according to 
the categories of the effect modifier.  
 
We fitted multivariable unconditional polytomous logistic regression models to 
evaluate differences in odds ratio estimates for ERPR-positive and ERPR-negative 
breast cancers (13). We have previously reported findings from the Women’s CARE 
Study that parity and breastfeeding had similar effects on breast cancer risk in White 
and African American women (9). We also found no apparent differences in the effect 
of parity and lactation on risk of ERPR-positive and ERPR-negative tumors by race 
(tests for heterogeneity of parity trends by race for risk of ERPR-positive or ERPR-
negative tumors for women aged <25 years or ≥25 years at first birth, P>0.15) and 
therefore we present the results for the races combined.  
 
All P-values reported are two-sided. Analyses were performed using the SAS® 
statistical package (Version 9.0, SAS institute, Cary, NC, USA) or EPILOG 
(Epicenter Software, Pasadena, CA). 
 
Results 
The distribution of women classified by race, parity status, number of full-term 
pregnancies and age at first full-term pregnancy varied between ERPR-positive cases, 
ERPR-negative cases and control subjects (Table 1).  
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Women who reported having at least one full-term pregnancy before age 25 years 
were at 36% reduced risk of breast cancer compared to nulligravida, while no such 
effect was seen for women with a first birth after age 25 years (Table 2).  Further, the 
statistically significant decreasing risk of breast cancer with increasing number of 
births was only seen in women who with a first birth before age 25 years (P for 
heterogeneity of parity trends by age at first full-term pregnancy = 0.001).  The 
protective effect of a first birth before age 25 years was restricted to ERPR-positive 
breast cancer (Table 2, OR=0.59, 95% CI=0.42-0.82, test for heterogeneity by ERPR 
status = 0.004). Similarly, the protective effect of multiparity among women with a 
first birth before age 25 years was also restricted to ERPR-positive breast cancers (P 
for trend = 0.0001), although the test for heterogeneity by ERPR status was not 
statistically significant (P= 0.06).  
 
No association was observed between giving birth for the first time at age 25 years or 
older and a woman’s overall risk of breast cancer compared to nulligravida (Table 2).  
However, women with a late age at first birth had a higher risk of ERPR-negative 
tumors than nulligravida (OR=2.07, 95% CI=1.03-4.16). Among parous women with 
a late age at first birth, risk of both ERPR-positive and ERPR-negative tumors 
increased with each additional birth although neither result was statistically significant 
(Table 2). 
 
Parous women who had breastfed had a non-significant lower risk of ERPR-positive 
tumors (OR=0.84, 95% CI=0.68-1.03) and ERPR-negative tumors (OR=0.84, 95% 
CI=0.63-1.12) than parous women who had not breastfed (Table 3). This association 
was statistically significant for women whose first birth was at age 25 years or older 
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(OR=0.62, 95% CI=0.43-0.89), but not for those who had their first birth at a younger 
age (OR=0.90, 95% CI=0.75-1.08) (Table 3); however, age at first birth did not 
significantly modify the effect of breastfeeding on parous women’s breast cancer risk 
(test for heterogeneity P=0.43, data not shown).  
 
When we stratified parous women into those who had breastfed and those who had 
not, and adjusted for the effect of multiparity, we found that among women who never 
breastfed those who gave birth at a later age had greater risk of all breast cancers than 
those with a first birth before the age of 20 years (trend test P= 0.01, Table 3). This 
trend was not observed among women who breastfed (trend test P=0.74), although 
this apparent effect modification by breastfeeding was not statistically significant (P 
for heterogeneity by breastfeeding = 0.32).   This pattern was stronger for ERPR-
positive cancers (trend test P=0.003), but again, the test for effect modification by 
breast feeding was not statistically significant (P=0.06). Multiparity reduced the risk 
of breast cancer among women who reported having breastfed (trend test P=0.007), 
but did not reduce risk among those who never breastfed (trend test P=0.58); this 
apparent effect modification by breastfeeding was not statistically significant 
(P=0.33), and was only observed for ERPR-positive tumors. Multiparity did not 
reduce the risk of ERPR negative cancers, even among those who breastfed.  
 
Because of the possibility that breastfeeding modifies the effects of multiparity and 
age at first birth, we assessed whether breastfeeding modified the effects of 
multiparity in women with a late first birth. We therefore stratified our analyses by 
age at first birth (under age 25/age 25 years or later) as well as breastfeeding status. In 
order to directly assess the differences in effects according to age at first birth, we 
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used the common reference group of women who had never been pregnant. Due to the 
small numbers of women in some of these subgroups, we collapsed the categories for 
number of births to 0, 1, 2 and 3 or more for these analyses.  
 
Breastfeeding did not modify the protective effect of multiparity in women who had 
their first birth before age 25 years (Table 4). Comparing this group of women to 
nulligravid women, multiparity was associated with a reduced risk of breast cancer for 
women who breastfed and for those who never breastfed (trend test P = 0.002 and 
0.0001, respectively).  
 
Repeating these analyses in women who began their families at or after 25 years, 
again comparing them to nulligavid women, we observed that women who did not 
breastfeed had a statistically significant higher risk of breast cancer if they had more 
than two children (Table 4).  This effect was statistically significant for both ERPR-
positive and ERPR-negative tumors although patient numbers were small in these 
subgroups (data not shown).  Further, the test for trend for increasing risk of breast 
cancer with each additional birth among women who gave birth at a late age and did 
not breastfeed did not reach statistical significance (P=0.06,  Table 4).  
 
Discussion  
To our knowledge, this is the first study to examine the combined effects of parity, 
breastfeeding, and age at first birth on ERPR-positive and ERPR-negative breast 
cancer. We have previously reported findings from the Women’s CARE Study among 
women aged 35-64 years, indicating that early age at first birth and multiparity reduce 
the risk of ERPR-positive tumors but not ERPR-negative tumors, while breastfeeding 
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reduces the risk of both tumor subtypes (3). In the present analysis, which was 
restricted to women aged 55 to 64 years, multiparity reduced the long term risk of 
breast cancer for women who experienced their first birth before age 25 years, but 
offered no protection for women with a later age at first birth. Further, the protective 
effect of multiparity in women who started their families early was confined to 
ERPR-positive tumors, while women whose first birth was at age 25 years or later 
were at an increased risk of ERPR-negative tumors. In addition we found some 
evidence that breastfeeding may modify the effects of multiparity and age at first 
birth, specifically that women who were older at first birth, had three or more 
children, and had not breastfed had an elevated risk of breast cancer, that was not 
observed in women who breastfed. However, these analyses were limited by small 
numbers.  
 
The evidence that young age at first birth and multiparity independently reduce the 
risk of breast cancer is substantial (14). A meta-analysis of 8 Nordic observational 
studies (5,568 cases) that included women of all ages has provided some evidence that 
multiparity has a protective effect for women who start their families at a young age, 
but a harmful effect for women who start their families at age 35 years and older (test 
for interaction, P=0.07) (15). Although our analysis included fewer breast cancer 
cases, it was restricted to women aged 55 to 64 years to allow us to examine the long 
term effects of parity and age at first birth. All breast cancers included in our analysis 
among women with a late age at first birth occurred more than 15 years after the last 
reported full-term pregnancy. We also used a lower cut-point for classifying late age 
at first birth (≥25 years), which may explain why we were able to show a statistically 
significant interaction.  
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Our finding that the protective effect of age at first birth and multiparity are confined 
to ERPR-positive cancers is consistent with a recent systematic review (1) and with a 
meta-analysis (2) of data from many studies (including the Women’s CARE Study). 
However, neither review found an association between late age at first birth and 
increased risk of ERPR-negative tumors. Several studies have reported that women 
with a late age at first birth (30-35 years) have a higher overall risk of breast cancer 
than nulliparous women (16-18). Our findings provide some support for these 
conclusions among women who never breastfed as discussed below.   
 
Results from a large prospective population-based cohort study (23,890 breast cancer 
cases) suggest a time delay in the protective effect of pregnancy of up to 27 years that 
anticipates women who begin their families at a late age will eventually attain a lower 
long-term risk of breast cancer than nulliparous women (19). Our results further 
suggest that the long-term protective effect of parity may apply to ERPR-positive 
tumors, but not ERPR-negative tumors.  
 
We found that a history of breastfeeding reduces the risk of breast cancer for women 
aged 55 to 64 years. Moreover, multiparity was associated with an increased risk of 
breast cancer in women with a late age at first full-term pregnancy who had not 
breastfed. The meta-analysis conducted by the Collaborative Group on Hormonal 
Risk Factors established that breastfeeding has a protective effect against breast 
cancer independent of the protective effect of multiparity (14). This effect was similar 
when women were stratified by categories of age, menopausal status or age at first 
birth. Our finding that breastfeeding may have a stronger protective effect in women 
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aged 55 to 64 years who began their families at a later age was not addressed in the 
Collaborative effort.  Our finding has several interpretations. Firstly, we examined 
many associations in our analyses, and therefore this observation could have been due 
to chance.  Another possible explanation is that the protective effect of breastfeeding 
is time-limited. Analysis of all women who participated in the CARE study (9), and 
results from another case-control study (20) showed that the effect of breastfeeding 
was stronger in younger women and decreased over time. Our finding is consistent 
with these results if we assume that women with an early age at first birth are more 
likely to complete their families, and therefore their breastfeeding years, earlier than 
women who begin their families at a later age.  A third explanation for our finding is 
that a true synergy exists between these factors, and that somehow lactation inhibits 
the harmful hormonal effects of late pregnancies on both tumor subtypes. We and 
others have previously suggested that the mechanisms by which breastfeeding 
protects against breast cancer must be different from those of parity and age at first 
birth since breast feeding protects against both ERPR-positive and ERPR-negative 
tumors, while parity and age at first birth only protect against ERPR-positive cancers. 
Breastfeeding may protect against breast cancer through hormonal mechanisms 
(delayed ovulation, increased breast differentiation or changing the hormonal 
environment of the breast); or directly, by excretion of carcinogenic agents (4,21,22). 
 
Given that women are increasingly starting their families at a later age, it is important 
to confirm this finding on the long-term effects of breastfeeding and how it may 
modify the effects of parity on risk of ERPR-positive and ERPR-negative tumors in 
this group of women.  In our study, 54% of parous cases and 59% of parous controls 
reported ever breastfeeding. This proportion is similar or slightly higher than that 
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reported by nine previous studies from the United States (14). The National Survey of 
Family Growth reported a breastfeeding rate of 55% in 1995, rising up to 67% for 
babies born between 1997-2000 (4). Encouragingly, women aged 30 years or over at 
the time of birth reported the highest breastfeeding rate in this survey (77.5%), 
however rates varied substantially by race with Non-Hispanic blacks reporting the 
lowest rates of breastfeeding (47%). 
 
Strengths of our study include the restriction of the study population to women aged 
55-64 years which allowed us to examine the long term effects of parity, after any 
short-term increase in risk that would immediately follow a term pregnancy.  Despite 
the large size of the Women’s CARE Study, our analyses were limited by the small 
number of cases in some categories after stratification by age at first full-term 
pregnancy and breastfeeding status. In particular, we had few cases with an older age 
at first term pregnancy and no history of breastfeeding (N=182) and estimates of the 
effect of multiparity in this group of women are surrounded by wide confidence 
intervals. These small numbers did not allow us to examine whether these 
associations varied by tumor ERPR-status.  
 
We had no data on ERPR status for 17.9% of case patients. Chu et al (2002) reported 
a similar proportion of patients with unknown ERPR status in their study of 123,732 
breast cancer cases from 11 SEER sites between 1992-1998 (7). Cases with data on 
ERPR status had fewer children (χ2 P=0.01), later age at first birth (P=0.0001), and 
breastfed longer (P=0.03) than those without data on ERPR status (3), but it is not 
clear if and how the lack of receptor information on these patients could have altered 
our results.  
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Another limitation is that our analyses involved many comparisons in subgroups of 
women stratified by age at first birth, breast feeding status and ERPR tumor status; 
therefore it is possible that our results represent false positive findings and 
confirmation from other (larger) observational studies is essential.  
 
Similar to other studies investigating the independent effects of parity and 
breastfeeding, we classified women according to whether they reported ever versus 
never breastfeeding (14). This included 7% of case patients and 6% of control 
subjects aged 55 to 64 years who breastfed for less than 2 weeks.  We have previously 
reported that longer breastfeeding duration is associated with reduced risk of ERPR-
positive and ERPR-negative tumors in the Women’s CARE Study with modest 
reductions observed for women who breastfed for less than 2 weeks (3).  However, 
the modifiying effects of breastfeeding we describe here were similar when we 
excluded those who breastfed for less than 2 weeks.   
 
ERPR status of tumors was determined by different laboratories at each study site. 
This may have introduced some measurement error due to variations in laboratory 
methods and conditions. However, any differences in measurement would be 
expected to be random and result in non-differential bias which may have obscured 
the associations we report here.  
 
In conclusion, this study suggests that the effect of parity on a woman’s long-term 
risk of ERPR-positive and ERPR-negative breast cancer is modified by age at first 
birth and possibly by breastfeeding. In women with a late first term pregnancy, our 
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finding that breast feeding offers broad protection against  breast cancer may be used 
to promote the benefits of breast feeding in this group of women.  
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Table 1:  Distribution of demographic and reproductive characteristics of 969 case patients with 
ERPR-positive and ERPR-negative breast cancer and control subjects aged 55-64 years in the 
Women’s CARE Study 
 Cases   N (%) Controls  N (%)  
Characteristic 
ERPR-positive  
 
ERPR-negative  
 N (%) P1 
 708 (73.1) 261 (26.9) 1455  
Reference age (years)     
55-59 349  (49.3) 148  (56.7) 772 (53.1)  
60-64 359  (50.7) 113  (43.3) 683 (46.9) 0.09 
Race     
White 542 (76.6) 143 (54.8) 961 (66.1)  
African American 166 (23.5) 118 (45.2) 494 (34.0) 0.0001 
Parity status2     
Nulligravid 72 (10.2) 11 (4.2) 107 (7.4)  
At least one full-term pregnancy 636 (89.8) 250 (95.8) 1348 (92.7) 0.005 
Number of full-term pregnancies     
1 86 (13.5) 25 (10.0) 147 (10.9)  
2 215 (33.8) 69 (27.6) 350 (26.0)  
3 157 (24.7) 68 (27.2) 345 (25.6)  
4+ 178 (28.0) 88 (35.2) 506 (37.5) 0.0004 
Age at first full-term pregnancy 
(years)     
≤ 19 165 (25.9) 93 (37.2) 454 (33.7)  
20-24 278 (43.7) 104 (41.6) 622 (46.1)  
25-29 142 (22.3) 37 (14.8) 190 (14.1)  
>30+ 51 (8.02) 16 (6.4) 82 (6.1) 0.0001 
Ever breastfed     
No  291(45.8) 113 (45.2) 555 (41.2)  
Yes 345 (54.3) 137 (54.8) 793 (58.8)  0.12 
 
ERPR= estrogen receptor-progesterone receptor 
1. P-value: Χ2 test for differences in the distribution of characteristics by case/control status; 2. Women 
with a history of short-term pregnancies <26weeks but no full-term pregnancies excluded (20 ERPR-
positive cases, 6 ERPR-negative cases and 43 controls). 
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Table 2: Associations between parity status and breast cancer stratified by age at first full-term pregnancy (< 25/ > 25 years) among all women aged 55-
64 years in the Women’s CARE Study, and by ERPR status1  
 
  All women  ERPR-positive  ERPR-negative  
 
Parity status 
Age at first < 25 yrs Age at first ≥ 25 yrs Age at first < 25 yrs Age at first ≥ 25 yrs Age at first < 25 yrs Age at first ≥ 25 yrs 
N (case/ 
control) 
OR  
(95% CI) 
N (case/
control) 
OR  
(95% CI) 
N  
(cases)
OR  
(95% CI) 
N 
(cases) 
OR  
(95% CI) 
N  
(cases)
OR  
(95% CI) 
N  
(cases)
OR  
(95% CI) 
Nulliparous2 140/107 1.00 140/107 1.00 72 1.00 72 1.00 11 1.00 11 1.00 
1+ full-term 
pregnancy 
970/1076 0.64  
(0.48-0.84) 
347/272 0.97 
(0.71-1.31) 
443 0.59 
(0.42-0.82) 
193 1.05 
(0.73-1.51) 
197 1.62 
(0.84-3.11) 
53 2.07 
(1.03-4.16) 
P heterogeneity ERPR-positive vs ERPR-negative  0.004  0.06    
P heterogeneity  <25 yr vs ≥ 25 yr  0.00007    0.00001    0.23 
No. full-term 
pregnancy 
         
1 93/68 1.00 90/79 1.00 41 1.00 45 1.00 11 1.00 14 1.00 
2 247/227 0.84 
(0.58-1.22) 
142/123 0.88 
(0.58.1.33) 
132 0.93 
(0.59-1.47) 
83 1.04 
(0.64-1.69) 
48 1.61 
(0.78-3.31) 
21 0.93 
(0.43-2.01) 
3 246/292 0.63 
(0.44-0.91) 
83/53 1.35 
(0.77-2.04) 
109 0.56 
(0.35-0.88) 
48 1.36 
(0.77-2.41) 
58 1.50 
(0.74-3.04) 
10 1.09 
(0.43-2.73) 
4+ 384/489 0.57 
(0.40-0.81) 
32/17 1.56 
(0.78-3.15) 
161 0.51 
(0.33-0.80) 
17 1.63 
(0.73-3.63) 
80 1.10 
(0.55-2.19) 
8 2.76 
(0.94-8.07) 
P trend   0.0001  
 
 0.13   0.0001 .  0.15   0.26   0.13  
P heterogeneity of trend ERPR-positive vs ERPR-negative  0.06  0.75     
P heterogeneity of trend  <25 yr vs ≥ 25 yr3 0.001    0.002    0.04 
 
CI= confidence interval; ERPR=estrogen receptor-progesterone receptor; OR=odds ratio 
1. All unconditional logistic regression models include categories of age, race, study site, education, age at menarche and first degree family history of breast 
cancer; 2. These models used all nulligravida as the referent group; 3. In addition to factors listed in (1), models include categories of age at first full-term 
pregnancy. 
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Table 3: Associations between age at first full-term pregnancy, number of full-term pregnancies and breast cancer risk, stratified by breast feeding 
status (ever/never), among parous women aged 55-64 years in the Women’s CARE Study, and by ERPR status1   
 
  All parous women  ERPR-positive  ERPR-negative  
 Never breastfed Ever breastfed  Never breastfed Ever breastfed Never breastfed Ever breastfed 
 N (case/ 
control) 
OR  
(95% CI) 
N (case/ 
control) 
OR  
(95% CI) 
N  
(cases)
OR 
(95% CI) 
N 
(cases) 
OR 
(95% CI) 
N  
(cases)
OR 
(95% CI) 
N 
(cases)
OR 
(95% CI) 
All parous 
women  
600/555 1.00 717/793 0.87  
(0.74-1.02)2
291 1.00 345/793 0.84  
(0.68-1.03) 
113 1.00 137 0.84  
(0.63-1.12) 
Age at first 
< 25 years 
418/427 1.00 552/649 0.90 
(0.75-1.08) 
190 1.00 253/649 0.91  
(0.71-1.15) 
85 1.00 112 0.82  
(0.60-1.14) 
Age at first 
≥ 25 years 
182/128 1.00 165/144 0.62  
(0.43-0.89) 
101 1.00 92/144 0.57  
(0.37-0.87) 
28 1.00 25 0.65  
(0.33-1.27) 
Age first full-term 
pregnancy (yrs) 
        
<20 139/161 1.00 265/293 1.00 55 1.00 110/293 1.00 32 1.00 61 1.00 
20-24 279/266 1.21 
(0.90-1.64) 
287/356 0.87  
(0.67-1.13) 
135 1.34 
(0.63-1.64) 
143/356 0.86  
(0.61-1.20) 
53 1.12 
(0.33-1.35) 
51 0.79  
(0.50-1.25) 
25-29 128/83 1.86 
(1.25-2.78) 
118/107 1.12 
(0.77-1.63) 
71 2.32 
(0.83-2.53) 
71/107 1.25  
(0.79-1.97) 
19 1.41 
(0.37-2.08) 
18 1.03  
(0.52-2.04) 
30+ 54/45 1.47 
(0.88-2.45) 
47/37 1.05  
(0.62-1.79) 
30 1.97 
(0.82-4.11) 
21/37 0.86  
(0.44-1.69) 
9 1.44 
(0.69-6.15) 
7 1.10  
(0.41-2.92) 
P trend   0.01  0.74  0.003   0.81  0.20  0.99 
P heterogeneity of trend ERPR-positive vs ERPR-negative  0.46  0.71    
P heterogeneity ever vs never breastfed                     0.32    0.06    0.66 
No. full-term 
pregnancies 
         
1 113/95 1.00 70/52 1.00 55 1.00 31 1.00 15 1.00 10 1.00 
2 194/167 1.02 
(0.71-1.47) 
195/183 0.82  
(0.53-1.25) 
104 1.12 
(0.72-1.75) 
111 0.95  
(0.56-1.61) 
33 1.56 
(0.77-3.14) 
36 1.23 
(0.56-2.71) 
3 153/134 1.02 
(0.69-1.50) 
176/211 0.66  
(0.42-1.01) 
75 1.06 
(0.65-1.74) 
82 0.62  
(0.36-1.07) 
36 2.21 
(1.06-4.61) 
32 0.94  
(0.42-2.11) 
4+ 140/159 0.90 
(0.61-1.35) 
276/347 0.61 
(0.40-0.93) 
57 0.85 
(0.50-1.44) 
121 0.58  
(0.34-0.99) 
29 1.50 
(0.69-3.25) 
59 0.89 
(0.41-1.93) 
P trend   0.58  0.007  0.41   0.004  0.32   0.32 
P heterogeneity of trend ERPR-positive vs ERPR-negative  0.11  0.35    
P heterogeneity of trend ever vs never breastfed        0.33    0.61    0.29 
 
CI=confidence interval; ERPR=estrogen receptor-progesterone receptor; OR=odds ratio. 
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1. Unconditional logistic regression used to calculate odds ratios (OR) and 95% confidence intervals (CI); models include categories of age, race, study site, 
education, age at menarche, family history of breast cancer, age at first full-term pregnancy and number of full-term pregnancies; 2. OR of ever breastfeeding as 
compared to parous women who have never breastfed. 
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Table 4: Associations between number of full-term pregnancies and breast cancer risk , stratified by age at first full-term pregnancy (</≥25 years) and 
breastfeeding status (ever/never), for all women aged 55-64 years in the Women’s CARE Study cases1   
 
    
All women  Never breastfed Ever breastfed 
No. full-term  
pregnancies2 
N 
(case/control) 
OR (95% CI) N  
(case/control) 
OR (95% CI) 
Age at first full-term pregnancy < 25 years 
0 140/107 1.00 140/107 1.00 
1 55/40 0.97 (0.59-1.59) 38/28 0.92 (0.52-1.62) 
2 127/114 0.81 (0.56-1.18) 120/113 0.76 (0.53-1.10) 
3+ 236/273 0.62 (0.44-0.86) 394/508 0.54 (0.40-0.73) 
P trend  0.002   0.0001  
P heterogeneity of trend ever vs never breastfed3  0.68 
Age at first full-term pregnancy ≥ 25 years 
0 140/107 1.00 140/107 1.00 
1 58/55 0.89 (0.56-1.41) 32/24 1.00 (0.55-1.84) 
2 67/53 0.99 (0.63-1.54) 75/70 0.77 (0.49-1.20) 
3+ 57/20 2.19 (1.22-3.96) 58/50 0.80 (0.50-1.29) 
P trend  0.06   0.24 
P heterogeneity of trend ever vs never breastfed3 0.04 
 
CI=confidence interval; OR=odds ratio 
1. Unconditional logistic regression used to calculate odds ratios (OR) and 95% confidence intervals (CI); models include categories of age, race, study site, 
education, age at menarche, family history of breast cancer; 2. These models used all nulligravida as the referent group; 3.Test for heterogeneity of parity trend 
effect by breastfeeding status among parous women. 
 
 
 
 
